Interchange Capital Partners LLC Has $29,000 Stock Holdings in Danaher Corporation $DHR

Key Points

• Interchange Capital Partners LLC significantly reduced its holdings in Danaher Corporation by 92.4%, selling 1,792 shares and leaving them with a total of 147 shares valued at $29,000.
• Institutional investors collectively own 79.05% of Danaher’s stock, with several firms, including Generali Asset Management and Ritholtz Wealth Management, increasing their stakes in the second quarter.
• Danaher’s quarterly earnings exceeded analysts’ expectations, reporting an EPS of $1.80 against a forecast of $1.64, along with a revenue of $5.94 billion for the quarter.

Interchange Capital Partners LLC trimmed its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 92.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 147 shares of the conglomerate's stock after selling 1,792 shares during the quarter. Interchange Capital Partners LLC's holdings in Danaher were worth $29,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Generali Asset Management SPA SGR lifted its stake in shares of Danaher by 15.0% in the 2nd quarter. Generali Asset Management SPA SGR now owns 62,997 shares of the conglomerate's stock valued at $12,444,000 after purchasing an additional 8,237 shares during the period. Tuttle Capital Management LLC lifted its stake in shares of Danaher by 14.9% in the 2nd quarter. Tuttle Capital Management LLC now owns 2,679 shares of the conglomerate's stock valued at $529,000 after purchasing an additional 348 shares during the period. Ritholtz Wealth Management lifted its stake in shares of Danaher by 28.7% in the 2nd quarter. Ritholtz Wealth Management now owns 8,327 shares of the conglomerate's stock valued at $1,645,000 after purchasing an additional 1,858 shares during the period. AEGON ASSET MANAGEMENT UK Plc increased its position in Danaher by 5.5% in the 2nd quarter. AEGON ASSET MANAGEMENT UK Plc now owns 152,837 shares of the conglomerate's stock valued at $30,179,000 after buying an additional 7,996 shares in the last quarter. Finally, JGP Wealth Management LLC increased its position in Danaher by 7.1% in the 2nd quarter. JGP Wealth Management LLC now owns 4,127 shares of the conglomerate's stock valued at $815,000 after buying an additional 275 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DHR has been the subject of a number of research analyst reports. UBS Group decreased their target price on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 target price on Danaher in a research report on Tuesday, September 2nd. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Danaher in a research report on Wednesday, October 8th. Evercore ISI boosted their target price on Danaher from $226.00 to $245.00 and gave the company an "outperform" rating in a research report on Tuesday, October 7th. Finally, Barclays reaffirmed an "overweight" rating and issued a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $244.60.

Danaher Stock Performance

Shares of DHR opened at $206.32 on Thursday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The stock has a 50 day moving average price of $201.18 and a two-hundred day moving average price of $197.19. The firm has a market capitalization of $147.73 billion, a P/E ratio of 43.90, a P/E/G ratio of 2.94 and a beta of 0.77. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher's dividend payout ratio is currently 27.23%.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.